Cancer Archives

News and Trends 16 Nov 2022

Immutep announces efti clinical results for non-small cell lung cancer

Immutep Limited has revealed what it says are compelling new clinical data from its TACTI-002 all-comer PD-L1 phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha in combination with MSD’s (Merck and Co., Inc., Rahway, N.J., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients with non-small cell lung cancer (NSCLC). The new data was […]

November 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership

Jnana Therapeutics has entered into a second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need. The company also announced the close of […]

November 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Researchers create mini ‘bone marrow in a dish’ to boost anti-cancer treatments

Scientists from Oxford University and the University of Birmingham in the U.K. have made the first bone marrow ‘organoids’ that capture the key features of human bone marrow. The technology, which is the subject of a patent application filed by University of Birmingham Enterprise, will allow for the screening of multiple anti-cancer drugs at the […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

First patient dosed in Nouscom colorectal cancer study

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab versus pembrolizumab alone. NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of mismatch repair/microsatellite instable high […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Biotheus enters agreement with Hansoh Pharma for bispecific antibody

Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, has entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus’ EGFR/MET bispecific antibody (also known as PM1080) in China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

Fooditive takes world first bee-free honey a step closer

Large scale production trials of the first bee-free honey will start in the New Year thanks to Dutch-based ingredients company, Fooditive. The process of mass-producing a bio-identical honey means that the need to intensively farm honeybees will be eliminated and Fooditive aims to beat a scalable, provenanced supply. Not only will it provide the benefits […]

November 15, 2022 - 2 minutesmins - By Liza Laws

News and Trends 14 Nov 2022

HUTCHMED announces positive gastric cancer study results in China

HUTCHMED (China) Limited has announced initial results from FRUTIGA, a phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial was positive, having met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Priothera’s Mocravimod improves survival for patients with hematological malignancies

Priothera, a biotechnology company developing its S1P receptor modulator compound Mocravimod, has announced that positive data from a clinical trial reinforces the potential for the drug to improve survival outcomes for patients with hematological malignancies. The study has been evaluating Mocramivod in allogeneic hematopoietic cell transplantation patients and was published in journal Transplantation and Cellular […]

November 14, 2022 - 2 minutesmins - By Liza Laws

Interview 14 Nov 2022

MaaT Pharma: leading the charge in microbiome therapeutics

The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech MaaT Pharma outlines the firm’s efforts to blaze a trail in clinical testing and manufacturing in the new field. The microbiome world recently made a regulatory step forward as Australia greenlit a stool transplant developed […]

November 14, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 14 Nov 2022

Altered cell behavior reason for neuroblastoma resistance

Researchers at Lund University in Sweden have identified one of the reasons why the childhood cancer neuroblastoma becomes resistant to chemotherapy. The scientists hope the findings are significant for how future treatments should be designed. The results have been published in the journal Science Advances. Neuroblastoma is an aggressive cancer of the sympathetic nervous system, […]

November 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Researchers discover protein facilitates relapse of pediatric brain tumors

The malignant brain tumor type medulloblastoma can become resistant to therapy, which can cause relapse. Researchers at Uppsala University in Sweden have discovered a protein that makes tumor cells insensitive to radiation treatment. The scientists hope the results could lead to better treatments for children with the highest risk to develop relapses. Avoiding treatment Medulloblastoma […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Immutep announces efti clinical results for non-small cell lung cancer

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership

Researchers create mini ‘bone marrow in a dish’ to boost anti-cancer treatments

First patient dosed in Nouscom colorectal cancer study

Biotheus enters agreement with Hansoh Pharma for bispecific antibody

Fooditive takes world first bee-free honey a step closer

HUTCHMED announces positive gastric cancer study results in China

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Priothera’s Mocravimod improves survival for patients with hematological malignancies

MaaT Pharma: leading the charge in microbiome therapeutics

Altered cell behavior reason for neuroblastoma resistance

Researchers discover protein facilitates relapse of pediatric brain tumors

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!